Contact:
4008465777
-
About Us
News & Events
-
04-21
Breakthrough in GLP-1 Global Expansion | Tonghua Dongbao's Liraglutide Injection Receives GMP Certification from Colombia
Recently, the liraglutide injection, developed by Tonghua Dongbao Pharmaceutical Co., Ltd. ("Tonghua Dongbao" or "the Company") and its partner, Kexing Biopharm Co., Ltd. ("Kexing Biopharm"), has rece...
-
04-03
Tonghua Dongbao: Dual-target inhibitor for gout (THDBH151 Tablets) completes phase IIa clinical trial summary report
Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd., a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company" or "Tonghua Dongbao"), recently completed a Phase IIa pivota...
-
03-23
Global Expansion | Tonghua Dongbao's Mixed Isophane Protamine Human Insulin Injection (30R) Approved for Marketing in Uzbekistan
Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company") recently received marketing approval for its Mixed Isophane Protamine Human Insulin Injection (30R) from the regulatory authorities of Uzbekist...
-
03-20
Tonghua Dongbao Doses the First Patient in Phase III Clinical Trials of Insulin Degludec/Liraglutide Injection
Tonghua Dongbao Pharmaceutical Co., Ltd. ("Tonghua Dongbao" or "the Company") has completed the Phase I clinical trial in China for Insulin Degludec/Liraglutide Injection following the receipt of a cl...
-
03-03
GLP-1 Global Expansion | Tonghua Dongbao's Liraglutide Injection Undergoes GMP Inspection by the Egyptian Ministry of Health and Population
Recently, the liraglutide injection, developed by Tonghua Dongbao Pharmaceutical Co., Ltd. ("Tonghua Dongbao" or "the Company") and its partner, Kexing Biopharm Co., Ltd. ("Kexing Biopharm"), received...
-
02-27
Tonghua Dongbao's THDBH120 Injection Meets Primary Endpoint in Phase Ib Trial for Type 2 Diabetes, Reducing HbA1c by 1.38% in Six Weeks
Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd., a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company" or "Tonghua Dongbao"), completed a Phase Ib pivotal clinical...